NAPKON Pediatrics Module
1.0.0 - trial-use
NAPKON Pediatrics Module - Local Development build (v1.0.0). See the Directory of published versions
Summary
Defining URL: | https://www.napkon.de/fhir/ValueSet/medication-pediatrics-atc-de |
Version: | 1.0.0 |
Name: | MedicationPediatricsATCDE |
Title: | Medication Pediatrics ATC DE |
Status: | Active as of 2021-09-23 |
Definition: | Medication used in the case of a of COVID-19 infection for a pediatric patient |
Publisher: | Charité - Universitätsmedizin Berlin |
Source Resource: | XML / JSON / Turtle |
References
This value set includes codes based on the following rules:
http://fhir.de/CodeSystem/bfarm/atc
Code | Display |
A01AD05 | Acetylsalicylsäure |
L04AC07 | Tocilizumab |
L04AC03 | Anakinra |
N01AX13 | Distickstoffmonoxid |
N01AX63 | Distickstoffmonoxid, Kombinationen |
http://fhir.de/CodeSystem/bfarm/atc
where concept is-a J06Bhttp://fhir.de/CodeSystem/bfarm/atc
where concept is-a C01Chttp://fhir.de/CodeSystem/bfarm/atc
where concept is-a J01http://fhir.de/CodeSystem/bfarm/atc
where concept is-a B02Bhttp://fhir.de/CodeSystem/bfarm/atc
where concept is-a B05http://fhir.de/CodeSystem/bfarm/atc
where concept is-a R03
This value set contains 792 concepts
Expansion based on http://fhir.de/CodeSystem/bfarm/atc v2021 (CodeSystem)
All codes in this table are from the system http://fhir.de/CodeSystem/bfarm/atc
Code | Display | Definition |
A01AD05 | Acetylsalicylsäure | |
L04AC07 | Tocilizumab | |
L04AC03 | Anakinra | |
N01AX13 | Distickstoffmonoxid | |
N01AX63 | Distickstoffmonoxid, Kombinationen | |
J06B | IMMUNGLOBULINE | |
J06BA | Immunglobuline, normal human | |
J06BA01 | Immunglobuline, normal human, zur extravasalen Anwendung | |
J06BA02 | Immunglobuline, normal human, zur intravasalen Anwendung | |
J06BB | Spezifische Immunglobuline | |
J06BB01 | Anti-D(rh)-Immunglobulin | |
J06BB02 | Tetanus-Immunglobulin | |
J06BB03 | Varicella/Zoster-Immunglobulin | |
J06BB04 | Hepatitis-B-Immunglobulin | |
J06BB05 | Tollwut-Immunglobulin | |
J06BB06 | Röteln-Immunglobulin | |
J06BB07 | Kuhpocken-Immunglobulin | |
J06BB08 | Staphylococcus-Immunglobulin | |
J06BB09 | Cytomegalievirus-Immunglobulin | |
J06BB10 | Diphtherie-Immunglobulin | |
J06BB11 | Hepatitis-A-Immunglobulin | |
J06BB12 | FSME-Immunglobulin | |
J06BB13 | Pertussis-Immunglobulin | |
J06BB14 | Masern-Immunglobulin | |
J06BB15 | Mumps-Immunglobulin | |
J06BB16 | Palivizumab | |
J06BB17 | Motavizumab | |
J06BB18 | Raxibacumab | |
J06BB19 | Anthrax-Immunglobulin | |
J06BB21 | Bezlotoxumab | |
J06BB22 | Obiltoxaximab | |
J06BB30 | Kombinationen | |
J06BC | Andere Immunglobuline | |
J06BC01 | Nebacumab | |
J06BC10 | Andere Immunglobuline | |
C01C | KARDIOSTIMULANZIEN, EXKL. HERZGLYKOSIDE | |
C01CA | Adrenerge und dopaminerge Mittel | |
C01CA01 | Etilefrin | |
C01CA02 | Isoprenalin | |
C01CA03 | Norepinephrin | |
C01CA04 | Dopamin | |
C01CA05 | Norfenefrin | |
C01CA06 | Phenylephrin | |
C01CA07 | Dobutamin | |
C01CA08 | Oxedrin | |
C01CA09 | Metaraminol | |
C01CA10 | Methoxamin | |
C01CA11 | Mephentermin | |
C01CA12 | Dimetofrin | |
C01CA13 | Prenalterol | |
C01CA14 | Dopexamin | |
C01CA15 | Gepefrin | |
C01CA16 | Ibopamin | |
C01CA17 | Midodrin | |
C01CA18 | Octopamin | |
C01CA19 | Fenoldopam | |
C01CA21 | Cafedrin | |
C01CA22 | Arbutamin | |
C01CA23 | Theodrenalin | |
C01CA24 | Epinephrin | |
C01CA25 | Ameziniummetilsulfat | |
C01CA26 | Ephedrin | |
C01CA27 | Droxidopa | |
C01CA29 | Orciprenalin | |
C01CA30 | Kombinationen | |
C01CA32 | Pholedrin | |
C01CA50 | Adrenerge und dopaminerge Mittel, Kombinationen | |
C01CA51 | Etilefrin, Kombinationen | |
C01CA55 | Norfenefrin, Kombinationen | |
C01CA58 | Oxedrin, Kombinationen | |
C01CA68 | Octopamin, Kombinationen | |
C01CA81 | Metamfepramon, Kombinationen | |
C01CB | Ephedrin-Derivate | |
C01CB01 | Ephedrin | |
C01CB04 | Oxilofrin | |
C01CB51 | Ephedrin, Kombinationen | |
C01CB54 | Oxilofrin, Kombinationen | |
C01CE | Phosphodiesterasehemmer | |
C01CE01 | Amrinon | |
C01CE02 | Milrinon | |
C01CE03 | Enoximon | |
C01CE04 | Bucladesin | |
C01CH | Homöopathische und anthroposophische Kardiostimulanzien | |
C01CH20 | Kombinationen | |
C01CX | Andere Kardiostimulanzien | |
C01CX06 | Angiotensinamid | |
C01CX07 | Xamoterol | |
C01CX08 | Levosimendan | |
C01CX09 | Angiotensin II | |
C01CX10 | Ipratropiumbromid | |
J01 | ANTIBIOTIKA ZUR SYSTEMISCHEN ANWENDUNG | |
J01A | TETRACYCLINE | |
J01AA | Tetracycline | |
J01AA01 | Demeclocyclin | |
J01AA02 | Doxycyclin | |
J01AA03 | Chlortetracyclin | |
J01AA04 | Lymecyclin | |
J01AA05 | Metacyclin | |
J01AA06 | Oxytetracyclin | |
J01AA07 | Tetracyclin | |
J01AA08 | Minocyclin | |
J01AA09 | Rolitetracyclin | |
J01AA10 | Penimepicyclin | |
J01AA11 | Clomocyclin | |
J01AA12 | Tigecyclin | |
J01AA13 | Eravacyclin | |
J01AA14 | Sarecyclin | |
J01AA15 | Omadacyclin | |
J01AA20 | Kombinationen von Tetracyclinen | |
J01AA56 | Oxytetracyclin, Kombinationen | |
J01AA57 | Tetracyclin, Kombinationen | |
J01B | AMPHENICOLE | |
J01BA | Amphenicole | |
J01BA01 | Chloramphenicol | |
J01BA02 | Thiamphenicol | |
J01BA51 | Chloramphenicol, Kombinationen | |
J01BA52 | Thiamphenicol, Kombinationen | |
J01C | BETALACTAM-ANTIBIOTIKA, PENICILLINE | |
J01CA | Penicilline mit erweitertem Wirkungsspektrum | |
J01CA01 | Ampicillin | |
J01CA02 | Pivampicillin | |
J01CA03 | Carbenicillin | |
J01CA04 | Amoxicillin | |
J01CA05 | Carindacillin | |
J01CA06 | Bacampicillin | |
J01CA07 | Epicillin | |
J01CA08 | Pivmecillinam | |
J01CA09 | Azlocillin | |
J01CA10 | Mezlocillin | |
J01CA11 | Mecillinam | |
J01CA12 | Piperacillin | |
J01CA13 | Ticarcillin | |
J01CA14 | Metampicillin | |
J01CA15 | Talampicillin | |
J01CA16 | Sulbenicillin | |
J01CA17 | Temocillin | |
J01CA18 | Hetacillin | |
J01CA19 | Aspoxicillin | |
J01CA20 | Kombinationen | |
J01CA51 | Ampicillin, Kombinationen | |
J01CE | Beta-Lactamase-sensitive Penicilline | |
J01CE01 | Benzylpenicillin | |
J01CE02 | Phenoxymethylpenicillin | |
J01CE03 | Propicillin | |
J01CE04 | Azidocillin | |
J01CE05 | Pheneticillin | |
J01CE06 | Penamecillin | |
J01CE07 | Clometocillin | |
J01CE08 | Benzylpenicillin-Benzathin | |
J01CE09 | Benzylpenicillin-Procain | |
J01CE10 | Phenoxymethylpenicillin-Benzathin | |
J01CE11 | Clemizol-Penicillin | |
J01CE30 | Kombinationen | |
J01CE52 | Phenoxymethylpenicillin, Kombinationen | |
J01CF | Beta-Lactamase-resistente Penicilline | |
J01CF01 | Dicloxacillin | |
J01CF02 | Cloxacillin | |
J01CF03 | Meticillin | |
J01CF04 | Oxacillin | |
J01CF05 | Flucloxacillin | |
J01CF06 | Nafcillin | |
J01CG | Beta-Lactamase-Inhibitoren | |
J01CG01 | Sulbactam | |
J01CG02 | Tazobactam | |
J01CR | Kombinationen von Penicillinen, inkl. Beta-Lactamase-Inhibitoren | |
J01CR01 | Ampicillin und Beta-Lactamase-Inhibitoren | |
J01CR02 | Amoxicillin und Beta-Lactamase-Inhibitoren | |
J01CR03 | Ticarcillin und Beta-Lactamase-Inhibitoren | |
J01CR04 | Sultamicillin | |
J01CR05 | Piperacillin und Beta-Lactamase-Inhibitoren | |
J01CR50 | Kombinationen von Penicillinen | |
J01D | ANDERE BETA-LACTAM-ANTIBIOTIKA | |
J01DB | Cephalosporine der 1. Generation | |
J01DB01 | Cefalexin | |
J01DB02 | Cefaloridin | |
J01DB03 | Cefalotin | |
J01DB04 | Cefazolin | |
J01DB05 | Cefadroxil | |
J01DB06 | Cefazedon | |
J01DB07 | Cefatrizin | |
J01DB08 | Cefapirin | |
J01DB09 | Cefradin | |
J01DB10 | Cefacetril | |
J01DB11 | Cefroxadin | |
J01DB12 | Ceftezol | |
J01DC | Cephalosporine der 2. Generation | |
J01DC01 | Cefoxitin | |
J01DC02 | Cefuroxim | |
J01DC03 | Cefamandol | |
J01DC04 | Cefaclor | |
J01DC05 | Cefotetan | |
J01DC06 | Cefonicid | |
J01DC07 | Cefotiam | |
J01DC08 | Loracarbef | |
J01DC09 | Cefmetazol | |
J01DC10 | Cefprozil | |
J01DC11 | Ceforanid | |
J01DC12 | Cefminox | |
J01DC13 | Cefbuperazon | |
J01DC14 | Flomoxef | |
J01DD | Cephalosporine der 3. Generation | |
J01DD01 | Cefotaxim | |
J01DD02 | Ceftazidim | |
J01DD03 | Cefsulodin | |
J01DD04 | Ceftriaxon | |
J01DD05 | Cefmenoxim | |
J01DD06 | Latamoxef | |
J01DD07 | Ceftizoxim | |
J01DD08 | Cefixim | |
J01DD09 | Cefodizim | |
J01DD10 | Cefetamet | |
J01DD11 | Cefpiramid | |
J01DD12 | Cefoperazon | |
J01DD13 | Cefpodoxim | |
J01DD14 | Ceftibuten | |
J01DD15 | Cefdinir | |
J01DD16 | Cefditoren | |
J01DD17 | Cefcapen | |
J01DD18 | Cefteram | |
J01DD51 | Cefotaxim und Beta-Lactamase-Inhibitoren | |
J01DD52 | Ceftazidim und Beta-Lactamase-Inhibitoren | |
J01DD54 | Ceftriaxon, Kombinationen | |
J01DD62 | Cefoperazon und Beta-Lactamase-Inhibitoren | |
J01DD63 | Ceftriaxon und Beta-Lactamase-Inhibitoren | |
J01DD64 | Cefpodoxim und Beta-Lactamase-Inhibitoren | |
J01DE | Cephalosporine der 4. Generation | |
J01DE01 | Cefepim | |
J01DE02 | Cefpirom | |
J01DE03 | Cefozopran | |
J01DF | Monobactame | |
J01DF01 | Aztreonam | |
J01DF02 | Carumonam | |
J01DH | Carbapeneme | |
J01DH02 | Meropenem | |
J01DH03 | Ertapenem | |
J01DH04 | Doripenem | |
J01DH05 | Biapenem | |
J01DH06 | Tebipenempivoxil | |
J01DH51 | Imipenem und Cilastatin | |
J01DH52 | Meropenem und Vaborbactam | |
J01DH55 | Panipenem und Betamipron | |
J01DH56 | Imipenem, Cilastatin und Relebactam | |
J01DI | Andere Cephalosporine und Peneme | |
J01DI01 | Ceftobiprolmedocaril | |
J01DI02 | Ceftarolinfosamil | |
J01DI03 | Faropenem | |
J01DI04 | Cefiderocol | |
J01DI54 | Ceftolozan und Beta-Lactamase-Inhibitoren | |
J01E | SULFONAMIDE UND TRIMETHOPRIM | |
J01EA | Trimethoprim und Derivate | |
J01EA01 | Trimethoprim | |
J01EA02 | Brodimoprim | |
J01EA03 | Iclaprim | |
J01EB | Kurz wirkende Sulfonamide | |
J01EB01 | Sulfaisodimidin | |
J01EB02 | Sulfamethizol | |
J01EB03 | Sulfadimidin | |
J01EB04 | Sulfapyridin | |
J01EB05 | Sulfafurazol | |
J01EB06 | Sulfanilamid | |
J01EB07 | Sulfathiazol | |
J01EB08 | Sulfathiourea | |
J01EB09 | Sulfacarbamid | |
J01EB11 | Formylsulfisomidin | |
J01EB20 | Kombinationen | |
J01EB59 | Sulfacarbamid, Kombinationen | |
J01EB70 | Andere kurzwirksame Sulfonamide, Kombinationen | |
J01EC | Mittellang wirkende Sulfonamide | |
J01EC01 | Sulfamethoxazol | |
J01EC02 | Sulfadiazin | |
J01EC03 | Sulfamoxol | |
J01EC20 | Kombinationen | |
J01EC52 | Sulfadiazin, Kombinationen | |
J01ED | Lang wirkende Sulfonamide | |
J01ED01 | Sulfadimethoxin | |
J01ED02 | Sulfalen | |
J01ED03 | Sulfametomidin | |
J01ED04 | Sulfametoxydiazin | |
J01ED05 | Sulfamethoxypyridazin | |
J01ED06 | Sulfaperin | |
J01ED07 | Sulfamerazin | |
J01ED08 | Sulfaphenazol | |
J01ED09 | Sulfamazon | |
J01ED11 | Sulfaclomid | |
J01ED20 | Kombinationen | |
J01EE | Kombinationen von Sulfonamiden und Trimethoprim, inkl. Derivate | |
J01EE01 | Sulfamethoxazol und Trimethoprim | |
J01EE02 | Sulfadiazin und Trimethoprim | |
J01EE03 | Sulfametrol und Trimethoprim | |
J01EE04 | Sulfamoxol und Trimethoprim | |
J01EE05 | Sulfadimidin und Trimethoprim | |
J01EE06 | Sulfadiazin und Tetroxoprim | |
J01EE07 | Sulfamerazin und Trimethoprim | |
J01EE51 | Sulfamethoxazol und Trimethoprim, Kombinationen | |
J01F | MAKROLIDE, LINCOSAMIDE UND STREPTOGRAMINE | |
J01FA | Makrolide | |
J01FA01 | Erythromycin | |
J01FA02 | Spiramycin | |
J01FA03 | Midecamycin | |
J01FA05 | Oleandomycin | |
J01FA06 | Roxithromycin | |
J01FA07 | Josamycin | |
J01FA08 | Troleandomycin | |
J01FA09 | Clarithromycin | |
J01FA10 | Azithromycin | |
J01FA11 | Miocamycin | |
J01FA12 | Rokitamycin | |
J01FA13 | Dirithromycin | |
J01FA14 | Flurithromycin | |
J01FA15 | Telithromycin | |
J01FA16 | Solithromycin | |
J01FA21 | Erythromycinstinoprat | |
J01FF | Lincosamide | |
J01FF01 | Clindamycin | |
J01FF02 | Lincomycin | |
J01FG | Streptogramine | |
J01FG01 | Pristinamycin | |
J01FG02 | Quinupristin/Dalfopristin | |
J01G | AMINOGLYKOSID-ANTIBIOTIKA | |
J01GA | Streptomycine | |
J01GA01 | Streptomycin | |
J01GA02 | Streptoduocin | |
J01GB | Andere Aminoglykoside | |
J01GB01 | Tobramycin | |
J01GB03 | Gentamicin | |
J01GB04 | Kanamycin | |
J01GB05 | Neomycin | |
J01GB06 | Amikacin | |
J01GB07 | Netilmicin | |
J01GB08 | Sisomicin | |
J01GB09 | Dibekacin | |
J01GB10 | Ribostamycin | |
J01GB11 | Isepamicin | |
J01GB12 | Arbekacin | |
J01GB13 | Bekanamycin | |
J01GB14 | Plazomicin | |
J01GB53 | Gentamicin, Kombinationen | |
J01GB55 | Neomycin, Kombinationen | |
J01GB69 | Framycetin, Kombinationen | |
J01M | CHINOLONE | |
J01MA | Fluorchinolone | |
J01MA01 | Ofloxacin | |
J01MA02 | Ciprofloxacin | |
J01MA03 | Pefloxacin | |
J01MA04 | Enoxacin | |
J01MA05 | Temafloxacin | |
J01MA06 | Norfloxacin | |
J01MA07 | Lomefloxacin | |
J01MA08 | Fleroxacin | |
J01MA09 | Sparfloxacin | |
J01MA10 | Rufloxacin | |
J01MA11 | Grepafloxacin | |
J01MA12 | Levofloxacin | |
J01MA13 | Trovafloxacin | |
J01MA14 | Moxifloxacin | |
J01MA15 | Gemifloxacin | |
J01MA16 | Gatifloxacin | |
J01MA17 | Prulifloxacin | |
J01MA18 | Pazufloxacin | |
J01MA19 | Garenoxacin | |
J01MA21 | Sitafloxacin | |
J01MA22 | Tosufloxacin | |
J01MA23 | Delafloxacin | |
J01MA24 | Levonadifloxacin | |
J01MA25 | Lascufloxacin | |
J01MB | Andere Chinolone | |
J01MB01 | Rosoxacin | |
J01MB02 | Nalidixinsäure | |
J01MB03 | Piromidsäure | |
J01MB04 | Pipemidsäure | |
J01MB05 | Oxolinsäure | |
J01MB06 | Cinoxacin | |
J01MB07 | Flumequin | |
J01MB08 | Nemonoxacin | |
J01R | KOMBINATIONEN VON ANTIBIOTIKA | |
J01RA | Kombinationen von Antibiotika | |
J01RA01 | Penicilline, Kombination mit anderen Antibiotika | |
J01RA02 | Sulfonamide, Kombination mit anderen Antibiotika (exkl. Trimethoprim) | |
J01RA03 | Cefuroxim und Metronidazol | |
J01RA04 | Spiramycin und Metronidazol | |
J01RA05 | Levofloxacin und Ornidazol | |
J01RA06 | Cefepim und Amikacin | |
J01RA07 | Azithromycin, Fluconazol und Secnidazol | |
J01RA08 | Tetracyclin und Oleandomycin | |
J01RA09 | Ofloxacin und Ornidazol | |
J01RA10 | Ciprofloxacin und Metronidazol | |
J01RA11 | Ciprofloxacin und Tinidazol | |
J01RA12 | Ciprofloxacin und Ornidazol | |
J01RA13 | Norfloxacin und Tinidazol | |
J01RA14 | Norfloxacin und Metronidazol | |
J01RA15 | Cefixim und Ornidazol | |
J01X | ANDERE ANTIBIOTIKA | |
J01XA | Glycopeptid-Antibiotika | |
J01XA01 | Vancomycin | |
J01XA02 | Teicoplanin | |
J01XA03 | Telavancin | |
J01XA04 | Dalbavancin | |
J01XA05 | Oritavancin | |
J01XB | Polymyxine | |
J01XB01 | Colistin | |
J01XB02 | Polymyxin B | |
J01XC | Steroid-Antibiotika | |
J01XC01 | Fusidinsäure | |
J01XD | Imidazol-Derivate | |
J01XD01 | Metronidazol | |
J01XD02 | Tinidazol | |
J01XD03 | Ornidazol | |
J01XE | Nitrofuran-Derivate | |
J01XE01 | Nitrofurantoin | |
J01XE02 | Nifurtoinol | |
J01XE03 | Furazidin | |
J01XE51 | Nitrofurantoin, Kombinationen | |
J01XX | Andere Antibiotika | |
J01XX01 | Fosfomycin | |
J01XX02 | Xibornol | |
J01XX03 | Clofoctol | |
J01XX04 | Spectinomycin | |
J01XX05 | Methenamin | |
J01XX06 | Mandelsäure | |
J01XX07 | Nitroxolin | |
J01XX08 | Linezolid | |
J01XX09 | Daptomycin | |
J01XX10 | Bacitracin | |
J01XX11 | Tedizolid | |
J01XX12 | Lefamulin | |
J01XX55 | Methenamin, Kombinationen | |
B02B | VITAMIN K UND ANDERE HÄMOSTATIKA | |
B02BA | Vitamin K | |
B02BA01 | Phytomenadion | |
B02BA02 | Menadion | |
B02BB | Fibrinogene | |
B02BB01 | Fibrinogen, human | |
B02BC | Lokale Hämostatika | |
B02BC01 | Absorbierbarer Gelatineschwamm | |
B02BC02 | Oxidierte Zellulose | |
B02BC03 | Tetragalacturonsäurehydroxymethylester | |
B02BC05 | Adrenalon | |
B02BC06 | Thrombin | |
B02BC07 | Kollagen | |
B02BC08 | Calciumalginat | |
B02BC09 | Epinephrin | |
B02BC12 | Thromboplastin | |
B02BC13 | Polyglycolsäure | |
B02BC14 | Gelatine | |
B02BC30 | Kombinationen | |
B02BC51 | Blutgerinnungsfaktoren, Kombinationen | |
B02BC57 | Kollagen, Kombinationen | |
B02BD | Blutgerinnungsfaktoren | |
B02BD01 | Blutgerinnungsfaktoren IX, II, VII und X in Kombination | |
B02BD02 | Blutgerinnungsfaktor VIII | |
B02BD03 | Faktor-VIII-Inhibitor-bypass-Aktivität | |
B02BD04 | Blutgerinnungsfaktor IX | |
B02BD05 | Blutgerinnungsfaktor VII | |
B02BD06 | Von Willebrand-Faktor und Blutgerinnungsfaktor VIII in Kombination | |
B02BD07 | Blutgerinnungsfaktor XIII | |
B02BD08 | Blutgerinnungsfaktor VIIa | |
B02BD09 | Nonacog alfa | |
B02BD10 | Von Willebrand-Faktor | |
B02BD11 | Catridecacog | |
B02BD12 | Trenonacog alfa | |
B02BD13 | Blutgerinnungsfaktor X | |
B02BD14 | Susoctocog alfa | |
B02BD15 | Octocog alfa | |
B02BD16 | Turoctocog alfa | |
B02BD17 | Simoctocog alfa | |
B02BD29 | Nonacog gamma | |
B02BD30 | Thrombin | |
B02BD31 | Moroctocog alfa | |
B02BD32 | Efmoroctocog alfa | |
B02BD33 | Albutrepenonacog alfa | |
B02BD34 | Eftrenonacog alfa | |
B02BD35 | Lonoctocog alfa | |
B02BD36 | Nonacog beta pegol | |
B02BD37 | Eptacog alfa (aktiviert) | |
B02BD38 | Rurioctocog alfa pegol | |
B02BD39 | Damoctocog alfa pegol | |
B02BD40 | Vonicog alfa | |
B02BD41 | Turoctocog alfa pegol | |
B02BP | Pflanzliche Antihämorrhagika | |
B02BP50 | Pflanzliche Antihämorrhagika, Kombinationen | |
B02BX | Andere systemische Hämostatika | |
B02BX01 | Etamsylat | |
B02BX02 | Carbazochrom | |
B02BX03 | Batroxobin | |
B02BX04 | Romiplostim | |
B02BX05 | Eltrombopag | |
B02BX06 | Emicizumab | |
B02BX07 | Lusutrombopag | |
B02BX08 | Avatrombopag | |
B02BX09 | Fostamatinib | |
B05 | BLUTERSATZMITTEL UND PERFUSIONSLÖSUNGEN | |
B05A | BLUT UND VERWANDTE PRODUKTE | |
B05AA | Blutersatzmittel und Plasmaproteinfraktionen | |
B05AA01 | Albumin | |
B05AA02 | Andere Plasmaproteinfraktionen | |
B05AA03 | Fluorocarbon-Blutersatzmittel | |
B05AA05 | Dextran | |
B05AA06 | Gelatine-haltige Mittel | |
B05AA07 | Hydroxyethylstärke | |
B05AA08 | Hämoglobin crosfumaril | |
B05AA09 | Hämoglobin raffimer | |
B05AA10 | Hämoglobin glutamer (Rind) | |
B05AA51 | Albumin, Kombinationen | |
B05AA55 | Dextran, Kombinationen | |
B05AA56 | Gelatine-haltige Mittel, Kombinationen | |
B05AA57 | Hydroxyethylstärke, Kombinationen | |
B05AX | Andere Blutprodukte | |
B05AX01 | Erythrozyten | |
B05AX02 | Thrombozyten | |
B05AX03 | Blutplasma | |
B05AX04 | Stammzellen aus Nabelschnurblut | |
B05AX05 | Granulozyten | |
B05AX06 | Leukozyten | |
B05AX07 | Vollblut | |
B05AX10 | Sonstige Blutprodukte | |
B05AX40 | Sonstige Blutprodukte ohne Pharmazentralnummer | |
B05AX41 | Erythrozyten ohne Pharmazentralnummer | |
B05AX42 | Thrombozyten ohne Pharmazentralnummer | |
B05AX43 | Blutplasma ohne Pharmazentralnummer | |
B05AX45 | Granulozyten ohne Pharmazentralnummer | |
B05AX46 | Leukozyten ohne Pharmazentralnummer | |
B05AX47 | Vollblut ohne Pharmazentralnummer | |
B05B | I.V.-LÖSUNGEN | |
B05BA | Lösungen zur parenteralen Ernährung | |
B05BA01 | Aminosäuren | |
B05BA02 | Fett-Emulsionen | |
B05BA03 | Kohlenhydrate | |
B05BA04 | Proteinhydrolysate | |
B05BA10 | Kombinationen | |
B05BA11 | Glucose | |
B05BA12 | Fructose | |
B05BA13 | Sorbitol | |
B05BA14 | Xylitol | |
B05BB | Lösungen mit Wirkung auf den Elektrolythaushalt | |
B05BB01 | Elektrolyte | |
B05BB02 | Elektrolyte mit Kohlenhydraten | |
B05BB03 | Trometamol | |
B05BB04 | Elektrolyte in Kombination mit anderen Mitteln | |
B05BB11 | Physiologische Kochsalzlösung | |
B05BB12 | Ringerlösung | |
B05BB13 | Ringerlactatlösung | |
B05BB14 | Ringeracetatlösung | |
B05BB53 | Trometamol, Kombinationen | |
B05BC | Osmodiuretika | |
B05BC01 | Mannitol | |
B05BC02 | Harnstoff | |
B05BC03 | Sorbitol | |
B05BC51 | Mannitol, Kombinationen | |
B05BC53 | Sorbitol, Kombinationen | |
B05C | SPÜLLÖSUNGEN | |
B05CA | Antiinfektiva | |
B05CA01 | Cetylpyridinium | |
B05CA02 | Chlorhexidin | |
B05CA03 | Nitrofural | |
B05CA04 | Sulfamethizol | |
B05CA05 | Taurolidin | |
B05CA06 | Mandelsäure | |
B05CA07 | Noxytiolin | |
B05CA08 | Ethacridinlactat | |
B05CA09 | Neomycin | |
B05CA10 | Kombinationen | |
B05CB | Salzlösungen | |
B05CB01 | Natriumchlorid | |
B05CB02 | Natriumcitrat | |
B05CB03 | Magnesiumcitrat | |
B05CB04 | Natriumbicarbonat | |
B05CB10 | Kombinationen | |
B05CX | Andere Spüllösungen | |
B05CX01 | Glucose | |
B05CX02 | Sorbitol | |
B05CX03 | Glycin | |
B05CX04 | Mannitol | |
B05CX05 | Heparin | |
B05CX10 | Kombinationen | |
B05D | LÖSUNGEN ZUR PERITONEALDIALYSE | |
B05DA | Isotone Lösungen | |
B05DB | Hypertone Lösungen | |
B05DB50 | Kombinationen | |
B05X | ADDITIVA ZU I.V.-LÖSUNGEN | |
B05XA | Elektrolytlösungen | |
B05XA01 | Kaliumchlorid | |
B05XA02 | Natriumbicarbonat | |
B05XA03 | Natriumchlorid | |
B05XA04 | Ammoniumchlorid | |
B05XA05 | Magnesiumsulfat | |
B05XA06 | Kaliumphosphat, inkl. Kombinationen mit anderen Kaliumsalzen | |
B05XA07 | Calciumchlorid | |
B05XA08 | Natriumacetat | |
B05XA09 | Natriumphosphat | |
B05XA10 | Magnesiumphosphat | |
B05XA11 | Magnesiumchlorid | |
B05XA12 | Zinkchlorid | |
B05XA13 | Salzsäure | |
B05XA14 | Dinatrium-1-glycerophosphat | |
B05XA15 | Kaliumlactat | |
B05XA16 | Kardioplege Lösungen | |
B05XA17 | Kaliumacetat | |
B05XA18 | Zinksulfat | |
B05XA19 | Kalium L-malat | |
B05XA21 | Natriumcitrat | |
B05XA30 | Kombinationen von Elektrolyten | |
B05XA31 | Elektrolyte in Kombination mit anderen Mitteln | |
B05XB | Aminosäuren | |
B05XB01 | Argininhydrochlorid | |
B05XB02 | Alanylglutamin | |
B05XB03 | Lysin | |
B05XC | Vitamine | |
B05XC30 | Kombinationen | |
B05XX | Andere Additiva zu i.v.-Lösungen | |
B05XX02 | Trometamol | |
B05XX03 | Blut und Organextrakte vom Kalb, inkl. Kombinationen | |
B05XX04 | Ethanol | |
B05Z | HÄMODIALYSEKONZENTRATE UND HÄMOFILTRATE | |
B05ZA | Hämodialysekonzentrate | |
B05ZA50 | Kombinationen | |
B05ZB | Hämofiltrate | |
B05ZB10 | Verschiedene Hämofiltrate | |
B05ZB50 | Kombinationen | |
R03 | MITTEL BEI OBSTRUKTIVEN ATEMWEGSERKRANKUNGEN | |
R03A | INHALATIVE SYMPATHOMIMETIKA | |
R03AA | Alpha- und Beta-Adrenozeptoragonisten | |
R03AA01 | Epinephrin | |
R03AA51 | Epinephrin, Kombinationen | |
R03AA52 | DL-Ephedrin, Kombinationen | |
R03AB | Nichtselektive Beta-Adrenozeptoragonisten | |
R03AB02 | Isoprenalin | |
R03AB03 | Orciprenalin | |
R03AB52 | Isoprenalin, Kombinationen | |
R03AB53 | Orciprenalin, Kombinationen | |
R03AC | Selektive Beta2-Adrenozeptoragonisten | |
R03AC02 | Salbutamol | |
R03AC03 | Terbutalin | |
R03AC04 | Fenoterol | |
R03AC05 | Rimiterol | |
R03AC06 | Hexoprenalin | |
R03AC07 | Isoetarin | |
R03AC08 | Pirbuterol | |
R03AC09 | Tretoquinol | |
R03AC10 | Carbuterol | |
R03AC11 | Tulobuterol | |
R03AC12 | Salmeterol | |
R03AC13 | Formoterol | |
R03AC14 | Clenbuterol | |
R03AC15 | Reproterol | |
R03AC16 | Procaterol | |
R03AC17 | Bitolterol | |
R03AC18 | Indacaterol | |
R03AC19 | Olodaterol | |
R03AH | Kombinationen von Sympathomimetika | |
R03AK | Sympathomimetika in Kombination mit Corticosteroiden oder anderen Mitteln, exkl. Anticholinergika | |
R03AK01 | Epinephrin und andere Mittel bei obstruktiven Atemwegserkrankungen | |
R03AK02 | Isoprenalin und andere Mittel bei obstruktiven Atemwegserkrankungen | |
R03AK03 | Fenoterol und Cromoglicinsäure, Dinatriumsalz | |
R03AK04 | Salbutamol und Cromoglicinsäure, Dinatriumsalz | |
R03AK05 | Reproterol und Cromoglicinsäure, Dinatriumsalz | |
R03AK06 | Salmeterol und Fluticason | |
R03AK07 | Formoterol und Budesonid | |
R03AK08 | Formoterol und Beclometason | |
R03AK09 | Formoterol und Mometason | |
R03AK10 | Vilanterol und Fluticasonfuroat | |
R03AK11 | Formoterol und Fluticason | |
R03AK12 | Salmeterol und Budesonid | |
R03AK13 | Salbutamol und Beclometason | |
R03AK14 | Indacaterol und Mometason | |
R03AL | Sympathomimetika in Kombination mit Anticholinergika inkl. Dreifachkombinationen mit Corticosteroiden | |
R03AL01 | Fenoterol und Ipratropiumbromid | |
R03AL02 | Salbutamol und Ipratropiumbromid | |
R03AL03 | Vilanterol und Umeclidiniumbromid | |
R03AL04 | Indacaterol und Glycopyrroniumbromid | |
R03AL05 | Formoterol und Aclidiniumbromid | |
R03AL06 | Olodaterol und Tiotropiumbromid | |
R03AL07 | Formoterol und Glycopyrroniumbromid | |
R03AL08 | Vilanterol, Umeclidiniumbromid und Fluticasonfuroat | |
R03AL09 | Formoterol, Glycopyrroniumbromid und Beclometason | |
R03AL10 | Formoterol und Tiotropiumbromid | |
R03AL11 | Formoterol, Glycopyrroniumbromid und Budesonid | |
R03AL12 | Indacaterol, Glycopyrroniumbromid und Mometason | |
R03B | ANDERE INHALATIVE MITTEL BEI OBSTRUKTIVEN ATEMWEGSERKRANKUNGEN | |
R03BA | Glucocorticoide | |
R03BA01 | Beclometason | |
R03BA02 | Budesonid | |
R03BA03 | Flunisolid | |
R03BA04 | Betamethason | |
R03BA05 | Fluticason | |
R03BA06 | Triamcinolon | |
R03BA07 | Mometason | |
R03BA08 | Ciclesonid | |
R03BA09 | Fluticasonfuroat | |
R03BA19 | Dexamethason | |
R03BB | Anticholinergika | |
R03BB01 | Ipratropiumbromid | |
R03BB02 | Oxitropiumbromid | |
R03BB03 | Stechapfel-haltige Zubereitungen | |
R03BB04 | Tiotropiumbromid | |
R03BB05 | Aclidiniumbromid | |
R03BB06 | Glycopyrroniumbromid | |
R03BB07 | Umeclidiniumbromid | |
R03BB08 | Revefenacin | |
R03BB54 | Tiotropiumbromid, Kombinationen | |
R03BC | Antiallergika, exkl. Corticosteroide | |
R03BC01 | Cromoglicinsäure | |
R03BC03 | Nedocromil | |
R03BX | Andere inhalative Mittel bei obstruktiven Atemwegserkrankungen | |
R03BX01 | Fenspirid | |
R03C | SYMPATHOMIMETIKA ZUR SYSTEMISCHEN ANWENDUNG | |
R03CA | Alpha- und Beta-Adrenozeptoragonisten | |
R03CA02 | Ephedrin | |
R03CA51 | Epinephrin, Kombinationen | |
R03CA52 | Ephedrin, Kombinationen | |
R03CA53 | Methylephedrin, Kombinationen | |
R03CB | Nichtselektive Beta-Adrenozeptoragonisten | |
R03CB01 | Isoprenalin | |
R03CB02 | Methoxyphenamin | |
R03CB03 | Orciprenalin** | |
R03CB51 | Isoprenalin, Kombinationen | |
R03CB53 | Orciprenalin, Kombinationen | |
R03CC | Selektive Beta2-Adrenozeptoragonisten | |
R03CC02 | Salbutamol | |
R03CC03 | Terbutalin | |
R03CC04 | Fenoterol | |
R03CC05 | Hexoprenalin | |
R03CC06 | Isoetarin | |
R03CC07 | Pirbuterol | |
R03CC08 | Procaterol | |
R03CC09 | Tretoquinol | |
R03CC10 | Carbuterol | |
R03CC11 | Tulobuterol | |
R03CC12 | Bambuterol | |
R03CC13 | Clenbuterol | |
R03CC14 | Reproterol | |
R03CC53 | Terbutalin, Kombinationen | |
R03CC54 | Fenoterol, Kombinationen | |
R03CC63 | Clenbuterol und Ambroxol | |
R03CK | Sympathomimetika und andere Mittel bei obstruktiven Atemwegserkrankungen | |
R03D | ANDERE MITTEL BEI OBSTRUKTIVEN ATEMWEGSERKRANKUNGEN ZUR SYSTEMISCHEN ANWENDUNG | |
R03DA | Xanthine | |
R03DA01 | Diprophyllin | |
R03DA02 | Cholintheophyllinat | |
R03DA03 | Proxyphyllin | |
R03DA04 | Theophyllin | |
R03DA05 | Aminophyllin | |
R03DA06 | Etamiphyllin | |
R03DA07 | Theobromin | |
R03DA08 | Bamifyllin | |
R03DA09 | Acefyllinpiperazin | |
R03DA10 | Bufyllin | |
R03DA11 | Doxofyllin | |
R03DA12 | Mepyramintheophyllinacetat | |
R03DA20 | Kombinationen von Xanthinen | |
R03DA50 | Andere Xanthine, Kombinationen excl. Psycholeptika | |
R03DA51 | Diprophyllin, Kombinationen | |
R03DA52 | Cholintheophyllinat, Kombinationen | |
R03DA53 | Proxyphyllin, Kombinationen exkl. Psycholeptika | |
R03DA54 | Theophyllin, Kombinationen exkl. Psycholeptika | |
R03DA55 | Aminophyllin, Kombinationen | |
R03DA57 | Theobromin, Kombinationen | |
R03DA63 | Coffein, Kombinationen exkl. Psycholeptika | |
R03DA73 | Proxyphyllin, Kombinationen mit Psycholeptika | |
R03DA74 | Theophyllin, Kombinationen mit Psycholeptika | |
R03DA82 | Etofyllin, Kombinationen mit Psycholeptika | |
R03DA90 | Andere Xanthine, Kombinationen mit Psycholeptika | |
R03DB | Xanthine und Sympathomimetika | |
R03DB01 | Diprophyllin und Sympathomimetika | |
R03DB02 | Cholintheophyllinat und Sympathomimetika | |
R03DB03 | Proxyphyllin und Sympathomimetika | |
R03DB04 | Theophyllin und Sympathomimetika | |
R03DB05 | Aminophyllin und Sympathomimetika | |
R03DB06 | Etamiphyllin und Sympathomimetika | |
R03DB12 | Etofyllin und Sympathomimetika | |
R03DB13 | Coffein und Sympathomimetika | |
R03DB20 | Verschiedene Xanthine und Sympathomimetika | |
R03DC | Leukotrienrezeptorantagonisten | |
R03DC01 | Zafirlukast | |
R03DC02 | Pranlukast | |
R03DC03 | Montelukast | |
R03DC04 | Ibudilast | |
R03DC53 | Montelukast, Kombinationen | |
R03DH | Homöopathische und anthroposophische Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung | |
R03DH10 | Verschiedene | |
R03DH20 | Kombinationen | |
R03DX | Andere Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung | |
R03DX01 | Amlexanox | |
R03DX02 | Eprozinol | |
R03DX03 | Fenspirid | |
R03DX05 | Omalizumab | |
R03DX06 | Seratrodast | |
R03DX07 | Roflumilast | |
R03DX08 | Reslizumab | |
R03DX09 | Mepolizumab | |
R03DX10 | Benralizumab | |
R03DX11 | Tezepelumab | |
R03DX50 | Andere systemische Antiasthmatika, Kombinationen |
Explanation of the columns that may appear on this page:
Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
Source | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
Code | The code (used as the code in the resource instance) |
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
Definition | An explanation of the meaning of the concept |
Comments | Additional notes about how to use the code |